Egide

Success of the Capital Increase - Seite 2

The gross proceeds of the capital increase are €1,921,561.20, including the issue premium, corresponding to the issuing of 2,956,249 new shares at a subscription price of €0.65 per new share.

The funds raised will in particular enable Egide to:

-    begin work on turning around its US subsidiaries;

-    recruit a sales team to boost sales;

-    finance the increase in its working capital requirement due to higher turnover.

In addition, proceeds from the capital increase may serve to refund the bond issue of €750,000.

Settlement of the transaction and admission of the new shares to trading on Euronext Growth are scheduled for 7 September 2023. The new shares will bear current dividend rights and will give entitlement, as of their issue date, to all distributions decided by Egide as of that date. They will be immediately fungible with Egide’s existing shares and will be traded on the same listing line under ISIN FR0000072373.

As of 7 September 2023, Egide’s share capital will thus be €6,651,558, divided into 13,303,116 shares with a par value of €0.5 each.

FINANCIAL TIMETABLE
 Extraordinary general meeting:                12 September 2023

Publication of results for the six months to 30 June 2023:                         26 October 2023

CONTACTS

Egide – Philippe Bringuier – CEO and CFO – [phone] – [e-mail]  

FIN’EXTENSO – Isabelle Aprile – Media Relations – [phone] – [e-mail]  

About the Egide Group – You can find all the latest news about the Group online at: www.egide-group.com and LinkedIn

Egide is an international group specialising in the manufacture of hermetic packages and heat-dissipating solutions for sensitive electronic components. We are active in cutting-edge markets with high technological barriers in all critical environments (thermal imaging, optoelectronics, hyper-frequency components, power packages, etc.). Egide is the only dedicated global player and has manufacturing operations in France and the United States.

Egide is listed on Euronext Growth Paris- ISIN: FR0000072373 - Mnemo: ALGID

Attachment

• Egide-Capital-increase-results-Press-Release-09052023-EN